{"transactions":[{"id":1586397,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2024-03-08T21:01:09.000Z","date":"2024-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":16965,"price":6.16,"value":104504.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":703002,"source":{"system":"sec-edgar","filing":"0001140361-24-012446","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036124012446/form4.xml","form_type":"4"}},{"id":1586396,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2024-03-08T21:01:09.000Z","date":"2024-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":16677,"price":6.12,"value":102063.24,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":719967,"source":{"system":"sec-edgar","filing":"0001140361-24-012446","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036124012446/form4.xml","form_type":"4"}},{"id":1602717,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2024-03-04T21:00:30.000Z","date":"2024-02-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":4935,"price":5.36,"value":26451.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021, of which 13,750 unvested RSUs will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) and (v) 360,845 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":736644,"source":{"system":"sec-edgar","filing":"0001140361-24-011193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036124011193/form4.xml","form_type":"4"}},{"id":1615242,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2024-02-27T21:03:23.000Z","date":"2024-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":8257,"price":5.26,"value":43431.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021, of which 13,750 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 355,780 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":741579,"source":{"system":"sec-edgar","filing":"0001140361-24-009843","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036124009843/form4.xml","form_type":"4"}},{"id":1685359,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2024-01-05T21:00:38.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":16908,"price":4.52,"value":76424.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 347,307 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":749836,"source":{"system":"sec-edgar","filing":"0001140361-24-001139","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036124001139/form4.xml","form_type":"4"}},{"id":1766981,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-10-03T21:00:25.000Z","date":"2023-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":15268,"price":3.58,"value":54659.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 154,687 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 333,277 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":766744,"source":{"system":"sec-edgar","filing":"0001140361-23-046742","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123046742/form4.xml","form_type":"4"}},{"id":1803316,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":192472,"price":3.66,"value":704447.52,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021."}],"balance_after":0,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":192472},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803315,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":150000,"price":3.71,"value":556500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.71,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803314,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":200000,"price":3.22,"value":644000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023."}],"balance_after":0,"derivative":{"exercise_price":3.22,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803313,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":85416,"price":2.92,"value":249414.72,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024."}],"balance_after":14584,"derivative":{"exercise_price":2.92,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":85416},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803312,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":83979,"price":2.35,"value":197350.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025."}],"balance_after":55021,"derivative":{"exercise_price":2.35,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":83979},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803311,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":97395,"price":1.67,"value":162649.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026."}],"balance_after":177605,"derivative":{"exercise_price":1.67,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":97395},"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803310,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":178184,"price":4.4527,"value":793399.8968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average price of sales on August 16, 2023. The shares were sold in multiple transactions at prices ranging from $4.40 to $4.535, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 317,608 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":782013,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803309,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":631078,"price":4.61,"value":2909269.58,"ownership":{"direct":true},"balance_after":960197,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803308,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":192472,"price":3.66,"value":704447.52,"ownership":{"direct":true},"balance_after":1591275,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803307,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":150000,"price":3.71,"value":556500.0,"ownership":{"direct":true},"balance_after":1398803,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803306,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":200000,"price":3.22,"value":644000.0,"ownership":{"direct":true},"balance_after":1248803,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803305,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":85416,"price":2.92,"value":249414.72,"ownership":{"direct":true},"balance_after":1048803,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803304,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":83979,"price":2.35,"value":197350.65,"ownership":{"direct":true},"balance_after":963387,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803303,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":true,"shares":97395,"price":1.67,"value":162649.65,"ownership":{"direct":true},"balance_after":879408,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1803302,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-08-17T21:30:44.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":211578,"price":4.5975,"value":972729.855,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive."}],"balance_after":782013,"source":{"system":"sec-edgar","filing":"0001140361-23-040321","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123040321/form4.xml","form_type":"4"}},{"id":1835637,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-07-05T21:00:49.000Z","date":"2023-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":15268,"price":3.69,"value":56338.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 529,186 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":993591,"source":{"system":"sec-edgar","filing":"0001140361-23-033191","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123033191/form4.xml","form_type":"4"}},{"id":1927488,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-04-04T21:08:03.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":15469,"price":3.31,"value":51202.39,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 216,563 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 513,515 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1008858,"source":{"system":"sec-edgar","filing":"0001140361-23-016460","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123016460/form4.xml","form_type":"4"}},{"id":1963012,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T21:30:50.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":270345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027."}],"balance_after":270345,"derivative":{"exercise_price":3.35,"expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":270345},"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":1963011,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-03-08T21:30:50.000Z","date":"2023-03-07","kind":"tax_withholding","acquired":false,"shares":16965,"price":3.4,"value":57681.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 247,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 498,047 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1024327,"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":1963010,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-03-08T21:30:50.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":135175,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1041292,"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":1963009,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-03-08T21:30:50.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":5000,"price":3.55,"value":17750.0,"ownership":{"direct":true},"balance_after":906117,"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":1963008,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-03-08T21:30:50.000Z","date":"2023-02-25","kind":"tax_withholding","acquired":false,"shares":7927,"price":3.42,"value":27110.34,"ownership":{"direct":true},"balance_after":911117,"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":1963007,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-03-08T21:30:50.000Z","date":"2023-02-25","kind":"tax_withholding","acquired":false,"shares":1559,"price":3.42,"value":5331.78,"ownership":{"direct":true},"balance_after":919044,"source":{"system":"sec-edgar","filing":"0001140361-23-010773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123010773/form4.xml","form_type":"4"}},{"id":2060209,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2023-01-06T21:00:24.000Z","date":"2023-01-04","kind":"tax_withholding","acquired":false,"shares":114222,"price":3.87,"value":442039.14,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 247,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 468,396 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":920603,"source":{"system":"sec-edgar","filing":"0001140361-23-000872","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036123000872/form4.xml","form_type":"4"}},{"id":2091004,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2022-12-09T16:41:18.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":6993,"price":2.86,"value":19999.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the December 2022 public offering of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 335,118 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1034825,"source":{"system":"sec-edgar","filing":"0001140361-22-045112","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122045112/form4.xml","form_type":"4"}},{"id":2144106,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2022-10-04T21:01:58.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":73678,"price":2.43,"value":179037.54,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's (continued)"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from prior footnote) continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 328,125 shares of common stock owned by the reporting person, which reflects previous purchases and prior net settlements upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1027832,"source":{"system":"sec-edgar","filing":"0001140361-22-036163","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122036163/form4.xml","form_type":"4"}},{"id":2271793,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2022-05-13T21:03:14.000Z","date":"2022-05-11","kind":"tax_withholding","acquired":false,"shares":51965,"price":1.43,"value":74309.95,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 180,225 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the \"Milestone-Based RSUs\") established by the Board of Directors, upon the recommendation of the"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) Compensation Committee of the Board of Directors, which shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 221,578 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1101510,"source":{"system":"sec-edgar","filing":"0001140361-22-019216","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122019216/form4.xml","form_type":"4"}},{"id":2317597,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2022-03-25T17:16:22.000Z","date":"2022-03-23","kind":"tax_withholding","acquired":false,"shares":37178,"price":1.46,"value":54279.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 315,090 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the \"Milestone-Based RSUs\") established by the Board of Directors, upon the recommendation"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) of the Compensation Committee of the Board of Directors, of which (x) 134,865 of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (y) 180,225 of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 138,678 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1153475,"source":{"system":"sec-edgar","filing":"0001140361-22-011251","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122011251/form4.xml","form_type":"4"}},{"id":2341488,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-09T17:58:50.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026."}],"balance_after":275000,"derivative":{"exercise_price":1.67,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001140361-22-008673","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122008673/form4.xml","form_type":"4"}},{"id":2341487,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2022-03-09T17:58:50.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 137,500 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 495,000 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continue from footnote 2) (iii) 405,000 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the \"Milestone-Based RSUs\") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continue from footnote 3) (iv) 47,207 RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continue from footnote 4) (vi) 85,946 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1190653,"source":{"system":"sec-edgar","filing":"0001140361-22-008673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036122008673/form4.xml","form_type":"4"}},{"id":2534455,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2021-10-26T07:00:43.000Z","date":"2021-10-25","kind":"purchase","acquired":true,"shares":30000,"price":1,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the October 2021 public offering of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 495,000 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(ii) 405,000 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the \"Milestone-Based RSUs\") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(iii) 63,936 RSUs granted on February 25, 2021, of which 55,000 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(iv) 30,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 71,565 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1065501,"source":{"system":"sec-edgar","filing":"0001140361-21-035380","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036121035380/form4.xml","form_type":"4"}},{"id":2554198,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2021-10-01T21:31:46.000Z","date":"2021-09-29","kind":"grant","acquired":true,"shares":405000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent RSUs that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to milestone-based vesting conditions (the \"Milestone-Based RSUs\") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 495,000 Time-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and that will be settled into common stock upon vesting; (ii) 405,000 Milestone-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (2) and that will be settled into common stock upon vesting; (iii) 63,936 RSUs granted on February 25, 2021, of which 55,000 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 30,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 41,565 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1035501,"source":{"system":"sec-edgar","filing":"0001140361-21-033355","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036121033355/form4.xml","form_type":"4"}},{"id":2554197,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"officer":true,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2021-10-01T21:31:46.000Z","date":"2021-09-29","kind":"grant","acquired":true,"shares":495000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to time based vesting conditions (the \"Time-Based RSUs\"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 (\"Initial Vesting Date\") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024."}],"balance_after":630501,"source":{"system":"sec-edgar","filing":"0001140361-21-033355","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000114036121033355/form4.xml","form_type":"4"}},{"id":2825886,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-01T21:01:02.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":139000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025."}],"balance_after":139000,"derivative":{"exercise_price":2.35,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":139000},"source":{"system":"sec-edgar","filing":"0001193805-21-000291","document":"e620326_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380521000291/e620326_4-lenz.xml","form_type":"4"}},{"id":2825885,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2021-03-01T21:01:02.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":63936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 63,936 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (iii) 36,142 shares of common stock owned by the reporting person."}],"balance_after":140078,"source":{"system":"sec-edgar","filing":"0001193805-21-000291","document":"e620326_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380521000291/e620326_4-lenz.xml","form_type":"4"}},{"id":3059993,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2020-08-12T08:02:18.000Z","date":"2020-08-11","kind":"purchase","acquired":true,"shares":4000,"price":2.965,"value":11860.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 40,000 RSUs granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting."}],"balance_after":76142,"source":{"system":"sec-edgar","filing":"0001193805-20-001004","document":"e619855_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380520001004/e619855_4-lenz.xml","form_type":"4"}},{"id":3231604,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-03T19:08:12.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024."}],"balance_after":100000,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-20-000286","document":"e619420_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380520000286/e619420_4-lenz.xml","form_type":"4"}},{"id":3231603,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2020-03-03T19:08:12.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 40,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 32,142 shares of common stock owned by the reporting person."}],"balance_after":72142,"source":{"system":"sec-edgar","filing":"0001193805-20-000286","document":"e619420_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380520000286/e619420_4-lenz.xml","form_type":"4"}},{"id":3279533,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2020-02-11T10:13:46.000Z","date":"2020-02-11","kind":"purchase","acquired":true,"shares":7142,"price":3.5,"value":24997.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the Issuer's public offering."}],"balance_after":32142,"source":{"system":"sec-edgar","filing":"0001193805-20-000129","document":"e619336_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380520000129/e619336_4-lenz.xml","form_type":"4"}},{"id":3516694,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Common Stock","published_at":"2019-05-21T07:12:06.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":5000,"price":4,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the Issuer's public offering."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001193805-19-000521","document":"e618480_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380519000521/e618480_4-lenz.xml","form_type":"4"}},{"id":3686597,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-25T21:31:40.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023."}],"balance_after":200000,"derivative":{"exercise_price":3.22,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001193805-19-000092","document":"e618166_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380519000092/e618166_4-lenz.xml","form_type":"4"}},{"id":3898234,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO"}}],"security":"Common Stock","published_at":"2018-06-11T07:08:48.000Z","date":"2018-06-08","kind":"purchase","acquired":true,"shares":5000,"price":4.78,"value":23900.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the Issuer's public offering."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193805-18-000818","document":"e618084_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380518000818/e618084_4-lenz.xml","form_type":"4"}},{"id":4062512,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-02-13T21:01:13.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022."}],"balance_after":150000,"derivative":{"exercise_price":3.71,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-18-000189","document":"e617683_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380518000189/e617683_4-lenz.xml","form_type":"4"}},{"id":4165294,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO"}}],"security":"Common Stock","published_at":"2017-11-13T13:49:20.000Z","date":"2017-11-09","kind":"purchase","acquired":true,"shares":6500,"price":2.15,"value":13975.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a purchase from the underwriters in the Issuer's public offering."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001193805-17-003453","document":"e617470_4-lenz.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380517003453/e617470_4-lenz.xml","form_type":"4"}},{"id":4288209,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-06-08T18:04:41.000Z","date":"2017-06-06","kind":"grant","acquired":true,"shares":192472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021."}],"balance_after":192472,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":192472},"source":{"system":"sec-edgar","filing":"0001193805-17-001061","document":"e616268_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380517001061/e616268_4-lenz.xml","form_type":"4"}},{"id":4442348,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":93306,"kind":"person","name":"LENZ BRIAN","position":1,"cik":"0001283260","reported_name":"LENZ BRIAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-16T20:08:07.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021."}],"balance_after":22500,"derivative":{"exercise_price":5,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001193805-17-000274","document":"e615800_4-lenz.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283260/000119380517000274/e615800_4-lenz.xml","form_type":"4"}}]}